The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, Victoria 3010, Australia.
J Physiol. 2013 Jan 1;591(1):77-91. doi: 10.1113/jphysiol.2012.243063. Epub 2012 Oct 8.
Cell replacement therapy for Parkinson's disease has predominantly focused on ectopic transplantation of fetal dopamine (DA) neurons into the striatum as a means to restore neurotransmission, rather than homotopic grafts into the site of cell loss, which would require extensive axonal growth. However, ectopic grafts fail to restore important aspects of DA circuitry necessary for controlled basal ganglia output, and this may underlie the suboptimal and variable functional outcomes in patients. We recently showed that DA neurons in homotopic allografts of embryonic ventral mesencephalon (VM) can send long axonal projections along the nigrostriatal pathway in order to innervate forebrain targets, although the extent of striatal reinnervation remains substantially less than can be achieved with ectopic placement directly into the striatal target. Here, we examined the possible benefits of using younger VM donor tissue and over-expression of glial cell-derived neurotrophic factor (GDNF) in the striatal target to improve the degree of striatal innervation from homotopic grafts. Younger donor tissue, collected on embryonic day (E)10, generated 4-fold larger grafts with greater striatal targeting, compared to grafts generated from more conventional E12 donor VM. Over-expression of GDNF in the host brain also significantly increased DA axonal growth and striatal innervation. Furthermore, a notable increase in the number and proportion of A9 DA neurons, essential for functional recovery, was observed in younger donor grafts treated with GDNF. Behavioural testing confirmed functional integration of younger donor tissue and demonstrated that improved motor function could be attributed to both local midbrain and striatal innervation. Together, these findings suggest there is significant scope for further development of intra-nigral grafting as a restorative approach for Parkinson's disease.
帕金森病的细胞替代疗法主要集中在外源性移植胎儿多巴胺(DA)神经元到纹状体作为一种恢复神经传递的方法,而不是同源移植到细胞丢失的部位,这将需要广泛的轴突生长。然而,外源性移植不能恢复多巴胺回路的重要方面,这对于控制基底神经节的输出是必要的,这可能是患者功能结果不理想和多变的原因。我们最近表明,胚胎中脑腹侧(VM)同源同种异体移植物中的 DA 神经元可以沿着黑质纹状体通路发出长轴突投射,以便将神经支配到前脑靶标,尽管纹状体再支配的程度仍然大大低于直接将外源性移植到纹状体靶标中所能达到的程度。在这里,我们研究了使用年轻的 VM 供体组织和在纹状体靶标中超表达胶质细胞源性神经营养因子(GDNF)来改善同源移植体对纹状体的神经支配的可能益处。与源自更传统的 E12 供体 VM 的移植物相比,在胚胎日(E)10 收集的年轻供体组织产生的移植物体积更大,且更倾向于纹状体。在宿主大脑中过表达 GDNF 也显著增加了 DA 轴突的生长和纹状体的神经支配。此外,在接受 GDNF 治疗的年轻供体移植物中,观察到 A9 DA 神经元的数量和比例显著增加,这对功能恢复至关重要。行为测试证实了年轻供体组织的功能整合,并表明运动功能的改善可以归因于局部中脑和纹状体的神经支配。总之,这些发现表明,进一步发展黑质内移植作为帕金森病的一种修复方法具有很大的潜力。